Browse our verified analytical, preclinical, and clinical drug evaluation pipelines optimized for international regulatory registration.
Modern pharmaceutical science is undergoing a structural paradigm shift toward standardized botanical actives and multi-target natural medicines, driven by advanced metabolomics and rigorous regulatory frameworks.
Regulatory agencies such as the US FDA (Botanical Drug Development Guidance) and EMA (HMPC guidelines) require exhaustive proof of batch-to-batch chemical fingerprint consistency, raw material origin tracking, and quantitative active marker thresholds, elevating the qualification threshold for global suppliers.
Global biopharma pipelines are aggressively pursuing botanical NDA avenues in metabolic syndromes, neurodegenerative maintenance, immuno-oncology adjuvants, and chronic inflammatory indications where synthetic single molecules face efficacy plateaus.
The worldwide valuation of specialized botanical drug CRO/CDMO integrations is expanding beyond $18.4 Billion, prompting multinational brand holders to secure trusted manufacturing partners with both agricultural upstream control and cGMP analytical compliance.
Integrating traditional botanical lineage with next-generation pharmaceutical extraction architectures enables unparalleled cost containment, batch stability, and time-to-market compression.
Direct access to GAP-certified native harvesting regions across China eliminates multi-tier trading markups, ensuring pristine authenticity and minimal raw material variance from origin to delivery.
Continuous countercurrent extraction, supercritical fluid chromatography, and automated freeze-drying arrays compress scale-up transition from 100g discovery lots to multi-ton commercial deliveries.
In-house quality management protocols align with US FDA 21 CFR Part 210/211 and EU GMP standards, generating complete audit trails, impurity profiling, and genotoxicity evaluations.
Comprehensive contract research in Hunan, coupled with deep supplier ecosystems, delivers average R&D expenditure savings of 40% compared to Western clinical development organizations.
From single active pharmaceutical ingredients (APIs) to consumer packaging, our technical pipelines support diverse target formats.
High-density botanical fractions designed for dietary supplements. Customized for bioavailability, neutral organoleptic profiles, and verifiable health claims through small-group human nutritional clinical trials.
Targeted multi-component phytochemical profiles supported by GLP toxicology, full-spectrum in vitro mechanism of action testing, pharmacokinetic assays, and Phase I–IV IND/NDA registration files.
Standardized, clean-label plant polyphenol, flavonoid, and triterpene extracts with demonstrated transdermal absorption, free radical mitigation, cellular collagen maintenance, and safety documentation.
Clear stage-gate progression ensures traceable milestones, measurable deliverables, and risk-mitigated technical evolution.
Determining targeted secondary metabolites across variations of climate, geography, harvest windows, and plant anatomical fractions.
Deliverable: Target Discovery & Sourcing ReportEstablishing high-resolution HPTLC, HPLC, and GC analytical frameworks with chromatographic fingerprint identification for raw botanical consistency.
Deliverable: Validated QC Assay ProtocolsIsolating active botanical constituents, refining purification protocols, maximizing extraction yields, and establishing stable dosage form formulations.
Deliverable: Scale-up Parameter MatrixCompleting LD50, acute/chronic systemic toxicity, in vitro micro-cellular tests, and in vivo efficacy validations in validated animal models.
Deliverable: GLP Preclinical DossierExecuting controlled human trials, double-blind efficacy studies, and safety profiling compliant with international Good Clinical Practice (GCP).
Deliverable: NDA Clinical Study DataManufacturing finished products (tablets, softgels, liquids, granules) or purified bulk ingredients under strict client intellectual property exclusivity.
Deliverable: Commercial CoAs & Finished GoodsDecades of contract delivery for market-leading pharmaceutical groups, university hospitals, and specialized botanical clinical research networks.
Clear answers to frequent questions from R&D directors, qualification auditors, and procurement teams evaluating our China CRO/CDMO services.
Select a specific development tier or laboratory capability below to submit an inquiry to our project management team.
